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Summary Lonidamine (LND) is a new anti-cancer drug which interferes with the energy-yielding processes of
tumour cells without affecting DNA replication. A total of 69 previously untreated patients with non-small cell
lung cancer (NSCLC) entered this study. LND was given orally as a single agent at doses ranging from 450 to
900 mg day-' until tumour progression (2 to > 1,402 days). Partial responses (PR) occurred in 7/69 patients
(10.1%); 4/25, 1/27 and 2/9 for epidermoid, adenocarcinoma and large cell cancer respectively. PR by stage
was 4/10, 1/3, 1/20 and 1/28 for stages I, II, III and IV, respectively. The median duration of response was 303
days (,>61 to > 338 days). The median survival for the whole group was 261 days. Toxicity was assessed in
all patients. No myelosuppression occurred. The main side-effects were myalgia (68%), loss of appetite (23%),
asthenia (20%) and testicular pain (13%). Doses above 450 mg day-' produced more severe side-effects
without any improvement in therapeutic activity.
Lonidamine (LND; 1 (2,4)-chlorobenzyl- 1H-indazole-3-
carboxylic acid) has been shown to exert anti-spermatogenic
(Coulston et al., 1975), anti-tumour (Silvestrini et al., 1983)
and embryotoxic (Scorza et al., 1982) activities in laboratory
animals. It inhibits the energy processes characteristic of
some tissues, such as the seminiferous epithelium and tumour
cells (De Martino et al., 1979). At active doses against sperm-
atogenesis it is practically devoid of toxic effects and other
marked pharmacological actions (Cioli et al., 1984). In phase
I studies the drug was adequately tolerated; myalgia was the
dose-limiting toxic effect (Band et al., 1984). This phase II
study was performed in order to ascertain the anti-tumour
activity of LND in patients with non-small cell lung cancer
(NSCLC). The report describes the completed study in detail;
brief preliminary descriptions have appeared earlier (Kokron
et al., 1984).
Materials and methods
From November 1981 to December 1983, 70 consecutive
patients with non-small cell lung cancer were admitted to the
study and followed up to December 1986.
Conditions for admission to the study were: informed con-
sent, no previous chemotherapy, inoperable stage of disease,
no indication for radiation therapy, absence of brain metas-
tases, measurable or evaluable lesions and histological or
cytological diagnosis of non-small cell lung cancer.
One patient was ineligible because of the presence of brain
metastases diagnosed after admission to the trial. The charac-
teristics of the remaining 69 patients (54 male and 15 female,
with median age of 62 years) are reported in Table I. No
patient had a performance status (PS) above 2 according to
WHO criteria (WHO, 1979). Histologically there were 29
epidermoid, 30 adenocarcinoma, five large-cell anaplastic,
three adenosquamous and two other types, according to
WHO classification (WHO, 1981). Ten patients were in stage
I, five in stage II, 21 in stage III and 33 in stage IV,
according to the TNM classification of the IUAC (1982). In
the patients with stage I there was a medical contraindication
for surgery, and because of their cell type differentiation
(adenocarcinoma or adenosquamous carcinoma) radio-
therapy was excluded. LND was administered at a daily dose
of 600-900 mg in 15 patients, and 450 mg in 54 patients, in
three divided doses (every 8 h). Two dose ranges were chosen
in order to have a preliminary impression of any differences
in toxicity and therapeutic activity. Treatment was continued
until tumour progression (up to 46.2 months). If myalgia
occurred, no steroids were given in our patients.
Table I reports the characteristics of the patients treated
with the two different dosage schedules. Upon termination of
LND treatment, 50 patients were not given any other drugs
which might influence the long-term results of the experi-
mental treatment and 11 patients underwent chemotherapy
without achieving any objective improvement.
Tolerance was assessed on the basis of clinical examin-
ations, laboratory tests (red cell count, total and differential
white cell count, haemoglobin, haematocrit, platelet count,
fasting blood sugar, creatinine, BUN, uric acid, bilirubin,
alkaline phosphatase, SGOT, SGPT, LDH, gamma-GT,
NA+, K+, Ca2 , Fe2 , Cu2+) and ECG.
Emergent symptoms and signs were graded according to
the WHO criteria (WHO, 1979). The parameters were
evaluated according to the following criteria: 0, Absent.
1, Mild; usually transient, requiring no special treatment and
not interfering with usual daily activities. 2, Moderate;
impairs usual activities but may be ameliorated by simple
therapeutic manoeuvres; patient may or may not require
interruption of treatment. 3, Severe. Interrupting usual
activities and requiring interruption of treatment with or
without control measures. 4, Life-threatening, requiring hos-
pitalisation.
Tumour response was assessed at monthly intervals
through clinical examinations, X-rays including tomography
and scans (bronchoscopy was performed only at baseline).
Response was evaluated according to the following criteria:
Complete response (CR), the disappearance of all known
disease, determined by two observations not less than
4 weeks apart. Partial response (PR), decrease in total
tumour size of 50% or more, determined by two observa-
tions not less than 4 weeks apart. In addition there must be
no appearance of new lesions or progression of any existing
lesions. Minor response (MR), over 25% but less than 50%
decrease in total tumour size determined by two observations
not less than 4 weeks apart. In addition there must be no
appearance of new lesions or progression of any existing
lesions. For measurable lesions the PR and MR tumour size
criteria are based upon the standard 'sum of the products of
the perpendicular diameters'. For evaluable, non-measurable
disease the decrease in tumour size was estimated (Miller et
al., 1983). No change (NC), less than 25% decrease in total
tumour size or less than 25% increase in the size of one or
more measurbale lesions. Progressive disease (PD), a 25% or
more increase in the size of one or more lesions, or the
appearance of new lesions.
Patients were considered evaluable for response after a
minimum of 4 weeks of therapy and evaluable for toxicity
from initiation of treatment.
Survival was measured from the start of treatment accord-
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Table I Characteristics of patients
Lonidamine
All patients 450 mgday-' 600-900 mg day-'
Total no. 69 54 15
Sex (number of patients)
Male 54 41 13
Female 15 13 2
Age (year)
Range 44-79 44-79 53-71
Median 62 62 62
Performance status Zubrod (number of patients)
0 3 3 0
1 42 33 9
2 24 18 6
Histotype
Epidermoid 29 22 7
Adenocarcinoma 30 26 4
Large cell 5 1 4
Adenosquamous 3 3 0
Others 2 2 0
Stage
1 10 10 0
11 5 5 0
111 21 19 2
IV 33 20 13
Prior therapy
Surgery 8 6 2
None 61 48 13
ing to the life-table method and statistical analysis performed
by the log rank test (Peto et al., 1977).
Results
Sixty-nine patients were evaluable for tolerance and 61 for
response.
Three patients refused the treatment because of side-effects
after 2 days (general indisposition), 3 days (nausea and myal-
gia) and 9 days (headache and myalgia), respectively.
Treatment was discontinued due to severe muscular pain
after 10 and 15 days in two patients, worsening of general
condition after 10 days in one patient and cholestatic jaund-
ice after 19 days in one patient. This last patient had a daily
dose of 900 mg LND; cholestasis normalised after discon-
tinuation of treatment and another 3 weeks. This patient's
survival from the beginning of LND was 157 days. One
further patient did not return for the first check-up and was
lost to follow-up. The remaining 61 patients were treated
with LND until tumour progression occurred (29 to . 1,402
days; median 144 days). No patient had a dose reduction.
Response according to stage, histotype and performance
status is reported in Table II. Partial response occurred in
seven of the 61 evaluable patients and minor response in 11.
The regressions consisted mainly of a shrinkage of lesions on
chest X-rays. Stages I and II showed a better response than
stages III and IV (PR 5/13 versus 2/38; P <0.02). Epider-
moid carcinomas appeared to respond better than adenocar-
cinomas (PR 4/25 versus 1/27). No definite correlation can be
made with the performance status even though patients with
the best performance status had the highest response rate.
The median duration of PR was 303 days (>61 to . 338
days). Five out of 25 patients with no change showed a
symptomatic improvement while on LND therapy: diminua-
tion of bone-pain, chest-pain, cough (twice) and improve-
ment of appetite, respectively.
The median survival for the whole group was 261 days, for
epidermoid carcinoma 232 days and for adenocarcinomas
201 days. In the adenocarcinoma subgroup the median sur-
vival of PR and MR was over 34 months longer than of NC
and PD (. 1,135 days versus 164 days). The incidence and
severity of emergent symptoms is reported in Table III.
Myalgia, gastrointestinal disturbances, loss of appetite,
asthenia and testicular pain, diminished hearing and joint-
pain were the most frequent symptoms due to LND. Myal- gias generally occurred within the first 2 days of treatment
and most of the other side-effects within a fortnight. In the
majority of cases they either remained at a tolerable level or
disappeared spontaneously after a few days, despite con-
tinued treatment. Grade 4 melena was observed in a patient with a history of peptic ulcer. Although the frequency of
myalgia, asthenia and testicular pain was similar at the two
dose levels tested, they were more severe at the higher level.
Increase of serum alkaline phosphatase was observed in
four cases (grade 1) and one case (grade 2) respectively.
Table 11 Response according to stage, histotype, daily dose and performance status (PS)
No. Stage Histotype PS of
Response cases I II III IV Epid. Aden. Others 0 1 2
PR 7 4 1 1 1 4 1 2 3 1 3 MR 11 2 0 3 6 5 5 1 0 8 3 NC 25 3 1 10 11 9 13 3 0 17 8 PD 18 1 1 6 10 7 8 3 0 11 7 NE 8 0 2 1 5 4 3 1 0 5 3 Total 69 10 5 21 33 29 30 10 3 42 24
J.UratlOn ot FK: median 303 (p61 to 338) days. Duration of MR: median 143 (>47 to > 1,386) days. PR, partial response; MR, minor response; NC, no change; PD, progressive disease; NE, not evaluable for response.318 0. KOKRON et al.
Table III Emergent symptoms observed in 69 treated patients
WHO grade
Type 1 2 3 4 %
Myalgia 18 19 10 - 68.1
Asthenia 5 5 4 - 20.3
Gastric disturbances 1 1 - - 2.9
Nausea/vomiting 4 2 - - 8.7
Testicular pain 1 5 1 - 12.9
Diminished hearing 1 2 - - 4.3
Dizziness 4 - - - 5.8
Headache 2 - - - 2.9
Tremors - 2 - - 2.9
Drowsiness 2 - - - 2.9
Erythema/rash 2 - - - 2.9
Diarrhea 2 - - - 2.9
Mastodynia I - - - 1.4
Scotoma I - - - 1.4
Loss of appetite 10 2 4 - 23.2
Drowsiness - I - - 1.4
Melena - - - Ia 1.4
Paraesthesia - I - - 1.4
Urinary frequency I - - - 1.4
Itch I - - - 1.4
Sweating I - - - 1.4
Hair loss I - - - 1.4
Joint pain - 1 2 - 4.3
Abdominal pain - I - - 1.4
aHistory of peptic ulcer.
There was increased serum bilirubin in one patient (grade 3),
BUN in three (grade 1), serum creatinine in one (grade 1),
serum LDH in one (grade 1) and uric acid in one (grade 1),
and in six patients with epidermoid cancer and progressive
disease hypercalcaemia occurred (four of them also had tem-
porary elevated serum calcium before LND treatment).
Discussion
Lonidamine, used a single agent, was shown to have an
activity against inoperable NSCLC in 11% of the evaluable
patients. Stages I and II responded better than stages III and
IV. Better results were obtained in epidermoid carcinomas
(PR = 16%). Daily doses above 450 mg induced more severe
side-effects without improvement in therapeutic activity.
As far as tolerance was concerned, despite the frequent
occurence of myalgias we never observed a grade 4 toxicity
even at high doses, and this side-effect, like all the others,
promptly disappeared with the suspension of treatment.
There was no evidence of myelosuppression. As far as
changes in renal and liver function tests were concerned,
although they are difficult to attribute to LND (we also
observed a normalisation of these parameters in patients with
abnormal basal values), their close monitoring is suggested.
LND combined with standard cytotoxic chemotherapy
may be expected to have favourable combination effects
because of the completely different mechanism of action and
different spectrum of toxicity. On the basis of the results
obtained in this study we have now started a randomised
trial on the combination of LND with chemotherapy in
NSCLC.
The authors wish to thank Dr Charles W. Young and Dr Marianne
Baldinelli for their helpful review and editing of the manuscript.
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